milieu of RA, are playing an even greater role than previously assumed.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic disease affecting joints, connective tissues, muscles, tendons and fibrous tissue. It is typically associated with some degree of immobility, persistent synovitis, inflammation and generation of autoantibodies and can be disabling and sometimes disfiguring [1] . The disease prevalence varies between 0.3 and 1 %, and despite advances in treatment over past few decades, as a result of its comorbidities, the life expectancy of patients is reduced by 3-10 years [2] . The risk factors can be classified into non-modifiable, such as genetic or gender-based categories, and modifiable, such as environmental or lifestyle-based categories. The majority of RA falls into those caused by genetic factors, while environmental factors add cumulatively to the risk of developing the disease [3, 4] .
The pathophysiology of RA is complex, perpetuated by an arsenal of cells whose functions have been altered often by RA-associated genes and/or environmental triggers and converted to autoimmune cells and complexes, or made to follow an inflammatory pathway [5, 6] . Prominent amongst the cytokine mediators of inflammation triggered by lymphocytic activities are tumour necrosis factor (TNF-α) and interleukins (IL-1, IL-6) [5] , resulting in increasing levels of oxidative stress [7] . Lipid parameters (e.g. cholesterol levels) of sufferers are also distinctly altered and resistant to potential modification [8] . The inflammatory processes Abstract Cytokines, lymphocytes, platelets and several biomolecules have long been implicated in the pathology of rheumatoid arthritis (RA), and the influences of antibody production and tagging, and cytokine, chemokine and enzyme production at specific rheumatoid joints were thought to be exclusive to the advancement of disease parameters. Another role player in RA is red blood cells (RBCs) which, of late, have been found to be involved in RA pathobiology, as there is a positive correlation between RBC counts and joint pathology, as well as with inflammatory biomarkers in the disease. There is also an association between RBC distribution width and the incidence of myocardial infarction amongst RA patients, and there is a change in the lipid distribution within RBC membranes. Of late, certain RBC-associated factors with previously obscure roles and cell-derived particles thought to be inconsequential to the other constituents of plasma were found to be active biomolecular players. Several of these have been discovered to be present in or originating from RBCs. Their influences have been shown to involve in membrane dynamics that cause structural and functional changes in both platelets and RBCs. RBC-derived microparticles are emerging entities found to play direct roles in immunomodulation via interactions with other plasma cells. These correlations highlight the direct influences of RBCs on exacerbating RA pathology. This review will attempt to shed more light on how RBCs, in the true inflammatory in turn alter the attributes and functions of platelets and red blood cells (RBCs), manifesting in the development of other progressive features of the disease [9, 10] . Research has already established that there is a positive relationship existing between platelet and RBC counts and the levels of erosion occurring in RA joints [11] . However, the capacity of inflammation to transform RBC into pathogenic cells has not fully been explored in RA.
Therefore, in the current manuscript, we performed a comprehensive search on MEDLINE, Google Scholar, Scopus and Web of Science, following the guidelines stipulated by Gasparyan and coworkers in 2011 [12] . We performed our search for the literature using keywords specific to the red blood cell (RBC) in rheumatoid arthritis, and the keywords were: erythrocyte rheumatoid arthritis, erythrocyte autoimmunity, erythrocyte platelet interaction, erythrocyte membrane, erythrocyte protein, erythrocyte microparticle, erythrocyte inflammation, lysophosphatidic acid. Figure 1 shows a layout of the current manuscript.
RBC pathology in relation to RA pathology
A prominent measure recommended by the American College of Rheumatology and utilized by rheumatologists through which disease activity may be monitored is the erythrocyte sedimentation rate (ESR), and this is affected by changes in the indices of blood cells, especially those of RBCs [13] . The ESR for RA patients is increased, as the inflammatory state causes platelets to be in a hyperstimulated state and induces clustering of immune cells and proteins, which have been shown to be markers of the disease process [14] . The predisposition to clotting is as a result of inflammation which increases the presence and activity of clotting factors [15] . A recent study demonstrated how raised levels of this marker directly correlated with the risk for heart failure in patients [16] . Properties like RBC size and the blood pH also affect the ESR, and these may be altered in the disease.
The inflammatory milieu in rheumatoid arthritis has been shown to affect RBCs [10, 17, 18] . Anaemia, a comorbidity in RA, is a result of increased eryptosis of bone marrow erythroid cells [19] . It has a prevalence of about 30 % and was found to be more frequently associated with chronic conditions [20] . In early stages, it is caused by IL-6 suppression of erythropoiesis in bone marrow, but this type does not contribute to mortality [21] . The direct cause of anaemia in chronic RA has therefore frequently been attributed to the same factors that propagate disease parameters.
In addition to effects that RA pathology causes to RBCs, evidence suggests that they are equally potent in their capacity to aggravate inflammation in situations where platelet influences were thought to dominate. Their numbers have been found to be directly correlated with degrees of cartilage erosion occurring in the rheumatoid synovium [11] , and there seems to be a direct link between the presence of these cells and inflammatory biomarkers in RA [22] and also on raising the risk for myocardial infarction amongst patients [23] .
RBCs maintain characteristic structures with the help of a phospholipid bilayer and several transmembrane proteins. Proteins, functioning as receptors or transporters, are responsible for the elastic and structural properties of RBCs, as well as their interactions with the biochemical milieu [24] . Some of these proteins such as calpastatin have the potential to stimulate inflammatory activities in other cells or become antigens in the autoimmune atmosphere of the RA patient's physiology [25, 26] .
The protein content in the rheumatoid circulation is staggering. The disease is characterized by predominance of acute-phase response proteins such as fibrinogen, amyloid proteins and the globulins over albumin [27] . RBCs in these patients have been shown to be affected by the presence of excessive amounts of proteins circulating in the blood, as well as the levels of generated free radicals [28] . Levels of these proteins have been found to be the most significant indicators of radiographic progression [29] . An integrinassociated protein CD47 was also found to be a mediator for fibrinogen interactions with RBC membranes [30] . Recent studies have unveiled the potential for high-concentration fibrinogen to affect membrane deformability and regulation of free radicals in the presence of acetylcholine [31, 32] . The adsorption of these proteins into RBC membranes within the RA circulation is also a possibility that cannot be ruled out [33] . Furthermore, adsorption of charged proteins has also been shown to affect the distribution of lipids within membranes [34] . The structure and interactions of RBCs may consequently be hampered by the transmembrane protein changes, a possible cause for the characteristic phenomenon of high sedimentation rates in plasma. The oxidative state of RBC membrane proteins in rheumatoid circulation is altered, resulting in the severe state of oxidative stress in RA [35] . Free radicals such as nitric oxide have been found to bind and exacerbate the oxidative states of RBCs [36] . Furthermore, an RBC carries an overall negative charge, which should enable it offset the influence of pro-inflammatory factors, but this charge is altered by raised levels of oxidative stress [35] . Ergothioneine, an active transporter of cations on the RBC membrane is found at significantly higher levels in RA patients compared to patients with other chronic inflammatory diseases [18] . On the other hand, protective glutathione reductase, normally produced by RBCs, is insufficient to cancel out effects of the toxic oxygen metabolites, resulting in lipid peroxidation [37] . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a critical metabolic enzyme affiliated with the membrane undergoes ADP ribosylation and is inhibited from participation in its multiple roles within the cell cycle [38] . With overwhelming oxidation of proteins responsible for reversing these effects, the cell cycle suffers and eryptotic pathways eventually ensue.
The lipid parameters of RBC membranes have also been shown to influence their inflammatory state and participation in thrombotic pathologies, and this is critical to RA plasma characterized by dyslipidaemia [39] . Lipids are particularly influential in modulating the levels of inflammation occurring in the disease and determining the occurrence of comorbidities [40] . It was revealed that the lipid distribution in RA plasma and RBC bilayers is altered, showing a decreased level of cholesterol and phospholipids when compared to healthy controls [17] . Studies have shown that the amounts of cholesterol incorporated into the cell's phospholipid bilayer can determine its capacity to express phosphatidylserine (PS) on the outer leaflet independent of ATP-driven flippases [41] . This supports the possibility that portions of the membrane are budding off to form microparticles (MPs). They have been described in several inflammatory diseases and could be involved in RA pathobiology [42] . Investigation of the proteome of these RBC-derived microparticles (RMPs) provides evidence that they occasionally carry the crucial band 3 protein, which increases the chances that they may also express Rh-associated CD47 and present fibrinogen as an antigen [43, 44] . Expression of PS on cell membranes has also been shown to play a role in influencing the electrostatic association of cationic ligands with the cell [45] . With the reduced quantities of cholesterol in RA RBCs, they are likely to show greater degrees of membrane pathology.
Lysophosphatidic acid (LPA), a recently described lipidderived potentiator of synovial events originating from platelets, has been described in RA [46] . Emerging studies of signalling pathways suggest that its production is triggered when phospholipase A2 (PLA2) hydrolyses and causes exposure of PS [47, 48] . This leads to the opening of calcium (Ca 2+ ) channels in the membrane, which activates calpain/calpastatin pathways and ends in vesiculation [49, 50] . This directly affects the deformability and aggregatory properties of the cells [51] . LPA has also been found capable of inducing RMP generation [52] . The composition of lipids and proteins of the RMPs is varied and affected by the membrane domains of the originating cell, which in turn determines its stimulatory signal on the target cell [53, 54] . The expression of PS by RBC membranes could also indicate disengagement in the some lipid associations critical to the maintenance of structure by underlying spectrin proteins, resulting in changes in membrane ultrastructure [55] .
Beyond the influence of inflammatory stress on these cells, RBCs also contribute directly to RA pathology through immunoregulation. They have been shown capable of regulating cell cycles of the CD4+ and CD8+ T cell population and releasing factors that promote their growth and survival [56] [57] [58] . RMPs were also recently implicated in immune cell activation in addition to initiating thrombin generation [59] . Lipid rafts and their constituents are also critical to determining constituent membrane proteins and therefore affect intercellular biochemical signalling. There is proof within the literature that T cell antigen receptors are influenced by similar modifications [60] . Taking into account what the literature says, and considering the substantial role T cell signalling contributes to the pathophysiology of the disease, we suggest that some signalling between RBC membranes and T cells might therefore have been taking place undetected. The participation of these cells in immune activities requires further study in RA. A proposed pathway to RBC membrane pathology and direct involvement in RA is described in Fig. 2 .
The influences of platelet MPs on immunity have been well investigated in the disease, and those from RBCs might therefore also play an important role in the disease. Considering the degree of lipid dysregulation occurring within RBC membranes, it is likely that many more undiscovered pathways are aggravating the autoimmune milieu. Figure 3 is a depiction of the implied interrelationships between RBCs and RA pathology.
Platelet contributions to RA pathology
The inflammatory milieu of rheumatoid plasma provides sufficient agonistic stimuli for platelets in RA. Their numbers and degree of activity have been found to be significantly amplified in the disease [9] . Thrombocytosis was found in a large proportion of RA patients, attributed mostly to their reduced survival and increased turnover rates [61] . Platelet numbers have been directly correlated with clinical and other investigative measures of disease activity such as ESR, C-reactive protein, rheumatoid factor, levels of leucocyte and acute-phase proteins but inversely associated with albumin and haemoglobin levels [62] . Their volumes have also been markedly correlated with disease activity [63] . Increased platelet volumes were found to be directly affiliated with the risk of cardiac complications and hypertension [9, 64] . This links them directly to the comorbidity risk of RA.
Platelets have the capacity to function as delivery vehicles for a plethora of chemokines, cytokines, growth factors, autocrine and paracrine moieties which may or may not be present in the surrounding serum, and their activation sustains autoimmune pathways [65, 66] . They are also capable of post-translational automodification of their mRNAs following release from megakaryocytes via activation by molecular signals common to oxidative or haemostatic pathways [67] . They enhance vascular permeability and release MPs, which have been implicated in aiding the formation of immune complexes via autoantigen expression [68, 69] . MPs were also found to be carriers of the C-type lectin-like receptor 2 (CLEC-2) as with the originating cells which enables cleavage of the platelet glycoprotein GPVI [70] . Whether this is required prior to activation via collagen binding is yet to be established. Their mitochondria are capable of promoting oxidative stress and increasing pathophysiologic functions in the cell [71] .
Platelet function in peripheral circulation has also been found to be different from its activity in the RA synovium. Hyperactive platelets and their products are found in higher proportions at inflammatory sites than in circulation [72] . While inflammatory pathways differ from haemostatic, they share several common mediators that may cause platelet functions to overlap [73] . Disease features like invasion of synovial membranes and angiogenesis indicate platelet participation [74] . Differential binding and functions of the platelet receptors within circulation are different from their functions in the rheumatoid synovium, causing corresponding variations in its degrees of activity within circulation of RA patients. understanding their biochemical and biomolecular associations is important to detect potential implications to RA pathophysiology. Far beyond the placid role allotted to these cells within circulation, their associations are proving to be critical to the disease parameters. The magnitude of RBC and platelet influences on pathology can be observed just based on their proximity within circulation. The αIIbβ3 platelet integrin proteins (GPIIbIIIa) are central to coagulation and fibrinogenesis and platelet interactions. However, following activation via collagen binding, these receptor's responses were found to be significantly enhanced by prothrombotic releasates from a suspension containing both platelets and RBCs [75] . The releasates contained greater amounts of ADP, ATP and thromboxane B2 (TX B2) than those derived from platelets acting alone [76] . These RBCinduced responses were found to be sustained even after the removal of the initial agonist trigger and following inhibition of TX synthesis. It has been established that majority of the cell-derived microparticles occurring within circulation and a few occurring within the synovial space, as described by investigators, originate from RBCs [77, 78] . These RMPs effected expansion of the T lymphocyte pool via antigen presentation. Some of those investigated were found to be carriers of complement proteins or tissue factors and were less sensitive to clearance by annexin V [79] . There is further evidence that they serve as vectors and modify activities within target cells [80] .
RBC and platelet interactions in RA
Interactions of these particles with platelets have also triggered thrombotic signalling [77, 81] . Assays of thrombin production were able to confirm that RBCs and their products were capable of independent thrombin generation, once stimulated [82, 83] . Several studies of other diseases confirm this role of consistent contribution to hypercoagulability by RBCs [84] [85] [86] . RBC MPs are also capable of inducing platelet hyperstimulation following collagen activation [76] . These RMPs were found capable of inducing ex vivo platelet-platelet aggregates [87] and sometimes express PS on their surface which enables platelet binding and activation and in turn modifies the chemokine ligands they carry [88] . With angiogenesis at inflamed joints being a direct consequence of disease progression, these cells gain direct access to each other's molecular and biochemical influences so there is likely exponentiation of stimulation. This could possibly be a mechanism through which adjacent RBCs elevate the inflammatory responses of the platelets within rheumatoid serum, in which variable volumes of degraded collagen are present [89] . Figure 4 depicts some of the physiological relationships described.
Similarities between the morphological characteristics of cells undergoing membrane dysregulation to those following eryptotic pathways suggest they share common biochemical players [90] . An example of this is thromboxane, which was found to stimulate RBCs by inducing PS exposure on their surfaces, followed by an increase in cytosolic calcium content [76] . These responses have been found to be associated with reduced membrane deformability, increased adhesion, formation of pathomorphologies and a precursor to eryptosis [91] [92] [93] . The PS exposure further increases the adherence of RBCs to platelets and induces thrombosis [93] . It is hence likely that structural variants and adhesive associations observable within the RA RBC pool could also be a result of this interaction-based effect.
Some adhesion proteins have been identified enabling direct contact between platelets and RBCs. Intercellular adhesion molecule 4 (ICAM-4 or CD242), a blood group antigen within the Landsteiner Wiener family of glycoproteins, was recently identified on RBC membranes enabling direct binding to the platelet's αIIbβ3 integrin [94, 95] adhesive potential to diverse other components of vasculature makes it a potential trigger of thrombotic and inflammatory pathways. This is likely a preceding step to platelet-enabled coagulation during thrombotic events while the residues are opsonised for phagocytosis during clot resolution. However, RBCs that have undergone eryptosis, especially due to glucose deprivation, have been found to bind platelet PS receptors and potentially reduce the solubility of the thrombus [93] . It is therefore possible that biophysical changes, adhesive associations and thrombotic events observable within RA vasculature could also be a result of this interaction-based effect.
The cumulative effect of RBC presence within the rheumatoid milieu is therefore important in understanding the disease. Studies of other chronic conditions have demonstrated that changes occur to the lipid and protein composition of its cell membrane which potentially contributes to disease course [96] [97] [98] . In RA, however, literature is sparse which demonstrate exclusive roles played by RBC-originating receptors, molecules and signalling pathways on the disease. A general overview of the relationships described in this manuscript is shown in Fig. 5 .
Conclusion and further research
It is probable that as a result of ex vivo protocols utilized in separating and purifying protein systems for analyses of intracellular and molecular events and interactions, certain biochemical processes are missed in the discovery of pathophysiological pathways [99] . Pharmaceutical researchers targeting molecular markers of disease frequently encounter their influences during inquiries into unforeseen treatment outcomes. Aspirin resistance has already been established to be partly due to contributions from RBCs [100] . A combination of biochemical signals from the cellular players in the disease and the RBCs own propensity to contribute pathogenic stimuli may therefore be identified through investigations of progressive RA. Perhaps a closer look at the molecular and biochemical factors present within and around RBCs using conditions most identical to those in vivo would be a more productive way of improving therapeutic outcomes. Investigations of antigen systems being targeted by immune cells may also uncover associations with the RBC [26] . With the advent of utilizing platelets as delivery vehicles for therapeutic modulators of synovial diseases, RBCs with their diverse molecular and biochemical contributions should not be left out.
This review aims to emphasize an existing gap in knowledge with respect to RBCs in RA. Future studies should ascertain the following: Are there other contributions of RBCs to RA and are there currently limitations to the evaluation of the factors present within or being produced by RBCs that make investigating their contributions to the disease onerous?
Existing studies frequently attribute MP origin to either platelets, monocytes or immune cells, but could there be other sources triggering their formation? Current literature is sparse with only one describing the proteome constitution of RBC-derived microparticles/microvesicles, and this is not in RA. Could further investigation discover the presence of other factors that may not originate from RBCs, platelets, plasma or immune cells? Which markers are specific for the identification of these vesicles and what procedures are likely to perform the most accurate analyses? If spectrin and other skeletal proteins are involved in the maintenance of membrane integrity, could they also be present in RA-derived RBC vesicles? What could this mean to the functionality of the RBC in RA? Are there differences in the composition of microparticles/microvesicles in different diseases and could their formation imply increased risk for other comorbidities? In summary, RBCs may not be directly culpable for RA pathogenesis, but they certainly are involved in advancing disease parameters, and their participation in the disease process should be explored further. 
